Nitric oxide scavenging by cell-free hemoglobin may be a primary factor determining hypertension in polycythemic patients

Free Radical Research

Volumn 48, Issue 2, 2014, Pages 230-238

  Rusak, T ^a   Misztal, T ^a   Piszcz, J ^a   Tomasiak, M ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Erythrocytapheresis; Free hemoglobin; Hypertension; Nitric oxide; Polycythemia vera

Indexed keywords

CELL FREE HEMOGLOBIN; HEMOGLOBIN; NITRATE; NITRIC OXIDE; NITRITE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD VISCOSITY; CATABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE; FEMALE; HEMATOCRIT; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POLYCYTHEMIA VERA;

AGED; BLOOD PRESSURE; BLOOD VISCOSITY; CASE-CONTROL STUDIES; CELL SEPARATION; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBINS; HUMANS; HYPERTENSION; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NITRIC OXIDE; PLATELET COUNT; POLYCYTHEMIA VERA;

EID: 84890018113     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.3109/10715762.2013.860225     Document Type: Article

References (35)

1. T Barbui, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European Leukemia. Net J Clin Oncol 2011; 29: 761-770.
2. Vannucchi A. Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med 2010; 5: 177-184.
3. James C, Ugo V, Le Cou e dic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Zhan H, Spivak JL. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. Clin Adv Hematol Oncol 2009; 7: 334-342.
5. Schafer A. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214-4222.
6. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments. Haematologica 2008; 93: 372-380.
7. Spivak J. Polycythemia vera: Myths, mechanisms, and management. Blood 2002; 100: 4272-4290.
8. Defouilloy C, Teiger E, Sediame S, Andrivet P, Roudot-Thoraval F, Chouaid C, et al. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. A m J Respir Crit Care Med 1 998; 1 57: 1 452-1 460.
9. Singel DJ, Stamler JS. Chemical physiology of blood fl ow regulation by red blood cells: The role of nitric oxide and S-nitrosohemoglobin. Annu Rev Physiol 2005; 67: 99-145.
10. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007; 87: 315-424.
11. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001; 357: 593-615.
12. Bohlen HG, Zhou X, Unthank JL, Miller SJ, Bills R. Transfer of nitric oxide by blood from upstream to downstream resistance vessels causes microvascular dilation. Am J Physiol Heart Circ Physiol 2009; 297: H1337-H1346.
13. Chen K, Piknova B, Pittman RN, Schechter AN, Popel AS. Nitric oxide from nitrite reduction by hemoglobin in the plasma and erythrocytes. Nitric Oxide 2008; 18: 47-60.
14. Diesen DL, Hess DT, Stamler JS. Hypoxic vasodilation by red blood cells: Evidence for an s-nitrosothiol-based signal. Circ Res 2008; 103: 545-553.
15. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, et al. Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest 2005; 115: 2099-2107.
16. Dejam A, Hunter CJ, Pelletier MM, Hsu LL, Machado RF, Shiva S, et al. Erythrocytes are the major intravascular storage sites of nitrite in human blood. Blood 2005; 106: 734-739.
17. Crawford JH, Isbell TS, Huang Z, Shiva S, Chacko BK, Schechter AN, et al. Hypoxia, red blood cells, and nitrite regulate NO-dependent hypoxic vasodilation. Blood 2006; 107: 566-574.
18. Helms C, Kim-Shapiro DB. Hemoglobin-mediated nitric oxide signaling. Free Radic Biol Med 2013; 61C: 464-472.
19. Azarov I, Liu C, Reynolds H, Tsekouras Z, Lee JS, Gladwin MT, Kim-Shapiro DB. Mechanisms of slower nitric oxide uptake by red blood cells and other hemoglobin-containing vesicles. J Biol Chem 2011; 286: 33567-33579.
20. Han TH, Pelling A, Jeon TJ, Gimzewski JK, Liao JC. Erythrocyte nitric oxide transport reduced by a submembrane cytoskeletal barrier. Biochim Biophys Acta 2005; 1723: 135-142.
21. Huang KT, Huang Z, Kim-Shapiro DB. Nitric oxide red blood cell membrane permeability at high and low oxygen tension. Nitric Oxide 2007; 16: 209-216.
22. Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: Role in blood fl ow regulation. Free Radic Biol Med 2004; 36: 707-717.
23. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: A novel mechanism of human disease. JAMA 2005; 293: 1653-1662.
24. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO, Schechter AN, Gladwin MT. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 1383-1389.
25. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: A meta-Analysis. JAMA 2008; 299: 2304-2312.
26. Beer PA, Campbell PJ, Green AR. Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase. Haematologica 2010; 95: 1960-1963.
27. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
28. Cella G, Marchetti M, Vianello F, Panova-Noeva M, Vignoli A, Russo L, et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost 2010; 104: 151-156.
29. Fairbanks VF, Ziesmer SC, O'Brien PC. Methods for measuring plasma hemoglobin in micromolar concentration compared. Clin Chem 1992; 38: 132-140.
30. Schmidt HHW, Kelm M. Determination of nitrite and nitrate by the Griess reaction. In: Feelisch M, Stamler JS (eds.). Methods in nitric oxide research. Chichester, UK: John Wiley & Sons, 1996. pp. 491-497.
31. Martini J, Carpentier B, Negrete AC, Frangos JA, Intaglietta M. Paradoxical hypotension following increased hematocrit and blood viscosity. Am J Physiol Heart Circ Physiol 2005; 289: H2136-H2143.
32. Salazar V a zquez BY, Cabrales P, Tsai AG, Johnson PC, Intaglietta M. Lowering of blood pressure by increasing hematocrit with non nitric oxide scavenging red blood cells. Am J Respir Cell Mol Biol 2008; 38: 135-142.
33. Owusu BY, Stapley R, Patel RP. Nitric oxide formation versus scavenging: The red blood cell balancing act. J Physiol 2012; 590: 4993-5000.
34. Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol 2006; 26: 697-705.
35. Pohl U, Lamontagne D, Bassenge E, Busse R. Attenuation of coronary autoregulation in the isolated rabbit heart by endothelium derived nitric oxide. Cardiovasc Res 1994; 28: 414-419.